553 / 1631
Early Relapse of Follicular Lymphoma After Rituximab Plus CHOP Defines
Patients at High Risk for Death: An Analysis From the National LymphoCare
Study.
Casulo C et al J Clin Oncol. 2015 Aug 10;33(23):2516-22
• 20% of patients with follicular lymphoma (FL) experience progression of
disease (POD) within 2 years of initial chemoimmunotherapy.
• National LymphoCare Study to identify whether prognostic FL factors are
associated with early POD and whether patients with early POD are at
high risk for death.
• 588 patients with stage 2 to 4 FL received first-line R-CHOP.
• Two groups were defined: patients with early POD 2 years or less after
diagnosis and those without POD within 2 years, the reference group.